Paper Details

  1. Home
  2. Paper Details

Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia.

Author: JamuarSaumya S, LaiAngeline H M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Deferiprone is an oral iron-chelating agent used to manage transfusion-related hemosiderosis, particularly in patients with thalassemia. It effectively reduces cardiac iron load and improves cardiac function. While generally well-tolerated, significant side effects like agranulocytosis, neutropenia, thrombocytopenia, and arthropathy can occur, requiring close monitoring and potential discontinuation of therapy.
Paper Details　
Original Abstract of the Article :
Deferiprone is an orally active iron-chelating agent used in the management of transfusion-related hemosiderosis. It has been in clinical use for over 20 years and has been shown to be effective in reducing cardiac iron load and improving cardiac function. As cardiac siderosis is the leading cause o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627318/

データ提供：米国国立医学図書館（NLM）

Iron Overload: Managing the Challenges of Transfusion-Dependent Thalassemia

Transfusion-dependent thalassemia, a complex blood disorder, can be likened to a desert oasis facing the threat of drought. This study explores the use of deferiprone, an orally active iron-chelating agent, in managing the iron overload associated with this condition. The authors highlight the effectiveness of deferiprone in reducing cardiac iron load and improving overall prognosis, offering a potential solution for individuals with this challenging disorder.

A Lifeline in the Desert: Managing Iron Overload

This research offers a beacon of hope for individuals living with transfusion-dependent thalassemia. The authors demonstrate the effectiveness of deferiprone in reducing cardiac iron overload, a major risk factor for this condition. This research is like finding a reliable source of water in a desert, offering a critical solution for managing this complex and often debilitating disorder.

Navigating the Side Effects: A Journey of Awareness

This study provides essential information for patients receiving deferiprone therapy. The authors acknowledge the potential side effects, like a desert traveler encountering unexpected obstacles. They emphasize the importance of regular monitoring and close collaboration with healthcare providers to manage any potential complications. This research promotes greater awareness and proactive management of this medication, ensuring that patients receive the best possible care.

Dr. Camel's Conclusion

This study explores the use of deferiprone, an iron-chelating agent, as a crucial tool for managing iron overload in individuals with transfusion-dependent thalassemia. The authors highlight the effectiveness of deferiprone in reducing cardiac iron load and improving overall prognosis, offering a potential lifeline in this challenging landscape. This research underscores the importance of understanding the potential side effects and maintaining open communication with healthcare providers to ensure optimal management of this medication.
Date :
  1. Date Completed 2013-04-26
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

23616917

DOI: Digital Object Identifier

PMC3627318

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.